Study of LYC-55716 in Adult Subjects With Locally Advanced or Metastatic Cancer
Public ClinicalTrials.gov record NCT02929862. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2A Multicenter, Open-Label Study of LYC-55716 in Adult Subjects With Locally Advanced or Metastatic Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 1/2A study designed to evaluate the safety and tolerability of increased repeated doses of LYC-55716 in subjects with locally advanced or metastatic solid tumors.
Study identification
- NCT ID
- NCT02929862
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 119 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 2016 (Type not available)
- Primary completion
- May 31, 2019 (Actual)
- Completion
- May 31, 2019 (Actual)
- Last update posted
- Sep 25, 2019
2016 – 2019
United States locations
- U.S. sites
- 20
- U.S. states
- 17
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Lycera Investigational Site | Huntsville | Alabama | 35805 | — |
| Lycera Investigational Site | Sacramento | California | 95817 | — |
| Lycera Investigational Site | Washington D.C. | District of Columbia | 20007 | — |
| Lycera Investigational Site | Sarasota | Florida | 34232 | — |
| Lycera Investigational Site | Atlanta | Georgia | 30322 | — |
| Lycera Investigational Site | Augusta | Georgia | 30912 | — |
| Lycera Investigational Site | Chicago | Illinois | 60611 | — |
| Lycera Investigational Site | Saint Cloud | Minnesota | 56303 | — |
| Lycera Investigational Site | Omaha | Nebraska | 68130 | — |
| Lycera Investigational Site | New York | New York | 10016 | — |
| Lycera Investigational Site | Durham | North Carolina | 27710 | — |
| Lycera Investigational Site | Oklahoma City | Oklahoma | 73104 | — |
| Lycera Investigational Site | Portland | Oregon | 97213 | — |
| Lycera Investigational Site | Philadelphia | Pennsylvania | 19111 | — |
| Lycera Investigational Site | Greenville | South Carolina | 29605 | — |
| Lycera Investigational Site | Nashville | Tennessee | 37203 | — |
| Lycera Investigational Site | Dallas | Texas | 75230 | — |
| Lycera Investigational Site | San Antonio | Texas | 78229 | — |
| Lycera Investigational Site | Charlottesville | Virginia | 22908 | — |
| Lycera Investigational Site | Fairfax | Virginia | 22031 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02929862, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 25, 2019 · Synced Nov 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02929862 live on ClinicalTrials.gov.